Literature DB >> 18383312

Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR).

Elizabeth C Chao1, Jonathan L Velasquez, Mavee S L Witherspoon, Laura S Rozek, David Peel, Pauline Ng, Stephen B Gruber, Patrice Watson, Gad Rennert, Hoda Anton-Culver, Henry Lynch, Steven M Lipkin.   

Abstract

Lynch syndrome, also known as hereditary nonpolyposis colon cancer (HNPCC), is the most common known genetic syndrome for colorectal cancer (CRC). MLH1/MSH2 mutations underlie approximately 90% of Lynch syndrome families. A total of 24% of these mutations are missense. Interpreting missense variation is extremely challenging. We have therefore developed multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR), a bioinformatic algorithm that effectively classifies MLH1/MSH2 deleterious and neutral missense variants. We compiled a large database (n>300) of MLH1/MSH2 missense variants with associated clinical and molecular characteristics. We divided this database into nonoverlapping training and validation sets and tested MAPP-MMR. MAPP-MMR significantly outperformed other missense variant classification algorithms (sensitivity, 94%; specificity, 96%; positive predictive value [PPV] 98%; negative predictive value [NPV], 89%), such as SIFT and PolyPhen. MAPP-MMR is an effective bioinformatic tool for missense variant interpretation that accurately distinguishes MLH1/MSH2 deleterious variants from neutral variants. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383312     DOI: 10.1002/humu.20735

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  57 in total

1.  Identification of Lynch syndrome mutations in the MLH1-PMS2 interface that disturb dimerization and mismatch repair.

Authors:  Jan Kosinski; Inga Hinrichsen; Janusz M Bujnicki; Peter Friedhoff; Guido Plotz
Journal:  Hum Mutat       Date:  2010-08       Impact factor: 4.878

2.  Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline.

Authors:  Scott M Weissman; Randall Burt; James Church; Steve Erdman; Heather Hampel; Spring Holter; Kory Jasperson; Matt F Kalady; Joy Larsen Haidle; Henry T Lynch; Selvi Palaniappan; Paul E Wise; Leigha Senter
Journal:  J Genet Couns       Date:  2011-12-14       Impact factor: 2.537

Review 3.  Clinical correlation and molecular evaluation confirm that the MLH1 p.Arg182Gly (c.544A>G) mutation is pathogenic and causes Lynch syndrome.

Authors:  Michael P Farrell; David J Hughes; Ian R Berry; David J Gallagher; Emily A Glogowski; Stewart J Payne; Michael J Kennedy; Róisín M Clarke; Susan A White; Cian B Muldoon; Fiona Macdonald; Pauline Rehal; Danielle Crompton; Solvig Roring; Sarah T Duke; Trudi McDevitt; David E Barton; Shirley V Hodgson; Andrew J Green; Peter A Daly
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

4.  Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

Authors:  Hinke F van Thuijl; Tali Mazor; Brett E Johnson; Shaun D Fouse; Koki Aihara; Chibo Hong; Annika Malmström; Martin Hallbeck; Jan J Heimans; Jenneke J Kloezeman; Marie Stenmark-Askmalm; Martine L M Lamfers; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchell S Berger; Peter Söderkvist; Barry S Taylor; Annette M Molinaro; Pieter Wesseling; Jaap C Reijneveld; Susan M Chang; Bauke Ylstra; Joseph F Costello
Journal:  Acta Neuropathol       Date:  2015-02-28       Impact factor: 17.088

5.  Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells.

Authors:  Abhijit Rath; Akriti Mishra; Victoria Duque Ferreira; Chaoran Hu; Gregory Omerza; Kevin Kelly; Andrew Hesse; Honey V Reddi; James P Grady; Christopher D Heinen
Journal:  Hum Mutat       Date:  2019-08-17       Impact factor: 4.878

6.  In silico analysis of missense substitutions using sequence-alignment based methods.

Authors:  Sean V Tavtigian; Marc S Greenblatt; Fabienne Lesueur; Graham B Byrnes
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

7.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

8.  Genetic evidence and integration of various data sources for classifying uncertain variants into a single model.

Authors:  David E Goldgar; Douglas F Easton; Graham B Byrnes; Amanda B Spurdle; Edwin S Iversen; Marc S Greenblatt
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes.

Authors:  Marc S Greenblatt; Lawrence C Brody; William D Foulkes; Maurizio Genuardi; Robert M W Hofstra; Magali Olivier; Sharon E Plon; Rolf H Sijmons; Olga Sinilnikova; Amanda B Spurdle
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

10.  Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.

Authors:  Hellen Houlleberghs; Marleen Dekker; Hildo Lantermans; Roos Kleinendorst; Hendrikus Jan Dubbink; Robert M W Hofstra; Senno Verhoef; Hein Te Riele
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.